Shots:

• The US FDA has granted FT designation to Triumvira’s TAC01-CD19 for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) prior treated with at least two systemic therapies
• The TAC technology will significantly improve the limitation of existing cell therapies- including the risk of cytokine release syndrome and neurotoxicity- expanding treatment option for the patients
• TAC01-CD19 is a novel T-cell therapy targeting CD19 with the expected onset of its P-I/II study (TACTIC-19) evaluating patients with CD19-positive B-cell malignancies- including DLBCL by the year-end 2019

Click here to­ read full press release/ article | Ref: Businesswire | Image: BusinessWire